INDIANAPOLIS– Nanosonics Ltd (ASX: NAN), a leader in infection prevention, is expanding its reach into Latin America with the addition of Juama S.A. de C.V. as its new distributor for the trophon®2 device, accessories, consumables and service in Mexico. Juama’s Medical Division, manufactures radiopharmaceuticals and represents internationally renowned brands in radiology, molecular imaging and infection prevention, such as Bayer, Siemens and now Nanosonics.
As a market leader in automated ultrasound reprocessing systems, Nanosonics’ trophon® technology helps protect patients by delivering consistent high level disinfection (HLD) of ultrasound probes with every automated cycle. Juama will be launching the next generation technology into this market, the trophon2, which offers an advanced user experience to deliver greater workflow efficiencies and demonstrated infection prevention compliance.
“We are pleased to have Juama represent our company and our innovative trophon HLD device in Mexico,” said Ken Shaw, president of North America for Nanosonics. “We are setting the global standard of care for ultrasound probe reprocessing, with over 26,750 trophon devices installed in over 30 countries. Every day approximately 88,000 patients are protected from the risk of ultrasound probe cross-contamination. This equates to an estimated 22 million patients annually.”
“Juama is very knowledgeable about the diagnostic imaging and infection prevention industry and will be an integral part of Nanosonics’ growth in this region,” continued Shaw.
“In partnering with Nanosonics, we can bring the global standard of care in HLD ultrasound probe decontamination to our customers,” said Juan Pablo Vilar, medical director for Juama. “We are honored to be a distributor for this pioneering company and its suite of HLD solutions proven to reduce risks of ultrasound probe cross infection while also being safe for our environment.”
The automated trophon device provides greater workflow efficiencies and traceability across the workflow environment for improved compliance and consistent patient protection. The device generates a sonically activated hydrogen peroxide mist that inactivates bacteria, mycobacteria, fungi, and viruses including pathogens that cause sexually transmitted infections (STIs) like high-risk human papillomavirus (HPV16 & 18).1,2 Moreover, more than 1,100 ultrasound probes from all major manufacturers are tested, approved and endorsed for use with trophon devices.
